Cetuximab, an inhibitor of EGFR, has been approved by the US Food and Drug Administration for the treatment of CRC with wild-type Kirsten rat sarcoma viral oncogene homolog (KRAS) and v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) genotypes [13]. This evidence concerns the gene EGFR and colorectal carcinoma.